Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-08-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于海创药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the listing and circulation of restricted shares from the initial public offering of Haichuang Pharmaceutical Co., Ltd. It includes specific details about the share types, shareholder commitments, share quantities, and compliance with relevant laws and regulations. The document is not an announcement of a report but a substantive verification opinion related to share circulation compliance. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or publication notice, so it is not RPA or RNS. The content focuses on the verification and compliance opinion related to share circulation, which fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories like capital update or director dealings.
2023-08-23 Chinese
自愿披露关于PROTAC药物HP518片获得药物临床试验申请受理通知书的公告
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure announcement by the company HaiChuang Pharmaceutical Co., Ltd. regarding the acceptance of a clinical trial application for their drug HP518 by the National Medical Products Administration. It contains no financial data, no financial statements, no management discussion of financial results, nor any regulatory certifications or voting results. It is a regulatory announcement about a clinical trial application acceptance, which is a general regulatory announcement about company operations and not a financial report or meeting material. The document length is short (1628 characters), and it is clearly an announcement of a regulatory event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-08-23 Chinese
首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the shareholders involved, and compliance with regulatory requirements. The document references regulatory approvals and includes a verification opinion from an intermediary institution. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The content fits the category of a regulatory announcement about share circulation and compliance rather than a financial report or management information. Therefore, it is best classified as a Regulatory Filing (RNS). The document length is 3715 characters, which is consistent with an announcement rather than a full report.
2023-08-23 Chinese
关于持股5%以上股东集中竞价减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a plan by a shareholder holding more than 5% of the company's shares to reduce their holdings through centralized bidding. It details the shareholder's current holdings, the planned reduction amount, timing, and reasons for the reduction. The document includes risk disclosures related to the share reduction plan and compliance with relevant securities laws and regulations. There are no financial statements, earnings data, or management discussion of financial results. The content fits the description of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds or planned reductions by large shareholders.
2023-06-16 Chinese
首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the dates, shareholder commitments, and regulatory compliance confirmations. The content focuses on share circulation and compliance with securities regulations rather than financial results, management changes, or other report types. The document length is relatively short (2525 characters) and it is a formal announcement about share circulation, not a financial report or detailed filing. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues, stock listing changes, or capital structure updates.
2023-06-07 Chinese
中信证券股份有限公司关于海创药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion from CITIC Securities regarding the unlocking and circulation of restricted shares from the initial public offering of Haichuang Pharmaceutical Co., Ltd. It details the types and quantities of restricted shares becoming tradable, shareholders' commitments, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion, but rather a regulatory compliance and verification statement related to share circulation post-IPO. It does not announce voting results, changes in management, or capital structure changes. It fits best as a Regulatory Filing (RNS) because it is a compliance and verification document that does not fit other specific categories and is relatively short (2535 characters).
2023-06-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.